Figure 1.
Abbreviations: IgAN, Immunoglobulin A nephropathy; SLE, systemic lupus erythematosus; TA-P, time-averaged proteinuria.
Table 1.
Patient characteristics according to time-averaged proteinuria.
Table 2.
Changes in eGFR, CKD stage, proteinuria, and blood pressure.
Table 3.
Clinical outcomes according to time-averaged proteinuria.
Figure 2.
The Kaplan–Meier renal survival curve of patients with IgAN according to time averaged proteinuria (TA-P).
Renal survival rates were lower as patients had greater amount of TA-P, particularly from TA-P>1.0 g/g. There was no significant difference in renal survival rate between patients with TA-P<0.3 g/g and TA-P of 0.3–0.99 g/g.
Table 4.
Multivariable Cox regression models for renal outcome of decline in eGFR>50%.
Figure 3.
The Kaplan–Meier renal survival curve of patients with IgAN according to baseline urine protein-to-creatinine ratio (UPCR) and time-averaged proteinuria (TA-P).
The 10-year renal survival rates were comparable between patients with TA-P of <0.3 g/g and those with TA-P of 0.3–0.99 g/g irrespective of their baseline UPCR. However, if patients had TA-P≥1 g/g during follow-up, their 10-year survival rates were significantly decreased even if they had a baseline UPCR<1.0 g/g.
Table 5.
Proteinuria reduction and renal outcome.
Table 6.
The rate of kidney function decline based on 4 categories of time-averaged proteinuria.